Facing Aricept Expiration, Eisai Maximizes Product Value
This article was originally published in PharmAsia News
Eisai is speeding up the launch of a new high-dose Aricept (donepezil) to maximize product value as the Alzheimer's disease drug will lose patent protection at the end of this month
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.